Synthetic cannabinomimetics and ‘legal highs’

  title={Synthetic cannabinomimetics and ‘legal highs’},
  author={Penelope Maxwell},
  journal={Journal of Pharmacy Practice and Research},
  • P. Maxwell
  • Published 1 December 2014
  • Medicine
  • Journal of Pharmacy Practice and Research
Synthetic cannabinomimetic compounds present unique challenges for both healthcare professionals and lawmakers. A case of a 16‐year‐old girl who had been admitted to John Hunter Hospital as a result of a psychosis after ingestion of a synthetic cannabinomimetic and other drugs prompted the review of a range of hitherto unanticipated legislative and drug policy issues for consideration of healthcare professionals. The challenges and options open to legislators and law enforcement agencies to… 
The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations.
A systems-based prevention approach is proposed that develops existing responses, is multilevel and life course informed in character, and emphasises commonalities between NPS and other legal and illegal drug use.
Identification and isolation of drugs in complex samples
This research developed platform technologies for forensic applications in drug detection and industrial pharmaceutical processing streams that will help improve the quality of investigations in the detection and processing of drugs and medicines.


Synthetic cannabinoids: The Australian experience
A wide range of legal ‘herbal’ products, claiming to have similar effects to cannabis, have been available in Australia for many years. Australian ‘head shops’ (retail outlets specialising in drug
Convulsions Associated with the Use of a Synthetic Cannabinoid Product
The absence of anticonvulsant phytocannabinoids in spice products could potentially be one of multiple unknown mechanisms contributing to convulsions.
Cannabinoid pharmacology: the first 66 years
  • R. Pertwee
  • Biology, Medicine
    British journal of pharmacology
  • 2006
Research into the pharmacology of individual cannabinoids that began in the 1940s is concisely reviewed and it is described how this pharmacological research led to the discovery of cannabinoid CB1 and CB2 receptors and of endogenous ligands for these receptors.
The endocannabinoid system: a general view and latest additions
The latest ‘additions’ to the endocannabinoid system are reviewed together with earlier breakthroughs that have contributed to the present knowledge of the biochemistry and pharmacology of theendocannabinoids.
Sydney: National Cannabis Prevention and Information Centre
  • Bulletin Series
  • 2012
Synthetic cannabinomimetics and 'legal highs'
This activity has been accredited for 1 hour of Group 2 CPD activity (or 2 CPD credits) suitable for inclusion in an individual pharmacist's CPD plan